PGDx, MolecularMD Ink Co-Marketing Deal

Oct 25, 2013

|

NEW YORK (GenomeWeb News) – Personal Genome Diagnostics today announced a deal with MolecularMD to market personalized medicine services to oncology researchers and drug developers.

The deal combines PGDx's expertise in next-generation sequencing-based cancer biomarker discovery with MolecularMD's capabilities in developing and validating cancer companion diagnostics, PGDx said. Under the agreement's terms, the two companies will co-market each other's services to drug manufacturers and biotechnology customers.

Further financial terms were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Getting It Early

Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.

Food Bugs to Meet Sequencers

The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.

From Ancient Bathrooms

Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.

This Week in Nature

In Nature this week: ash dieback disease fungal genome, and more.

Jun

12

Featured Webinar

Bridging the Gap Between Testing and Treatment in Precision Oncology

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Jun

28

Featured Webinar

An Optimized NGS Workflow for Human Metagenomic Analysis

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.

Main menu